Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Celsion Corp. (CLSN) To Present ThermoDox HEAT Study Results At Conference 0 comments
    Jul 11, 2013 2:18 PM | about stocks: CLSN

    Celsion is focused on the development and commercialization of innovative cancer drugs. These include tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. The company has research, license, or commercialization agreements with the National Institutes of Health and a number of universities around the world.

    The company announced today that Ronnie T.P. Poon, MD, MS, PhD, FRCS, FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion's Phase III HEAT Study of ThermoDox in hepatocellular carcinoma will present the clinical trial results at the International Liver Cancer Association seventh annual conference being held in Washington D.C. September 14, 2013.

    This association is the only international organization devoted solely on liver cancer research for experts from the medical, surgical oncology, interventional, and hepatology disciplines. Two members of the executive committee - Dr. Morris Sherman and Professor Riccardo Lencioni - along with Dr. Poon are the principal investigators on the Phase III HEAT Study of ThermoDox.

    Celsion has conducted a thorough analysis of the data from the Phase III study on approximately 300 patients with primary liver cancer. Data coming to light from the HEAT Study demonstrates that ThermoDox markedly improves positive progression free survival and overall survival in patients if their lesions undergo radio-frequency ablation for 45 minutes or more in combination with ThermoDox, which is thermally sensitive liposomal doxorubicin (releasing the drug at a few degrees above body temperature).

    Further information about Celsion Corporation, ThermoDox, and other products in development can be found at celsion.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: CLSN
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.